NCT04447222: Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must have participated in one of the following clinical trials: NCT00507923, NCT01202851, NCT02079662

Comments are closed.

Up ↑